Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)

Leprosy Clinical Trial

— BE-PEOPLE P2  

Official title:

Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy: Phase 2 Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05406479
• Other study ID #: BE-PEOPLE Phase 2
• Status: Completed
• Phase: Phase 2
• Start date: July 14, 2022
• Est. completion date: January 26, 2023

Study information

• Verified date: June 2023
• Source: Institute of Tropical Medicine, Belgium
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate a combination of bedaquiline and rifampicin as post exposure prophylaxis (PEP) for leprosy in Comoros. It will be a follow-up to the PEOPLE trial on PEP with rifampicin, which is ending in 2022. This new trial will be called the 'Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy' or 'BE-PEOPLE' trial. There will be two main study arms, a comparator arm based on the current WHO recommendation of providing a single dose of rifampicin (10 mg/kg) to close contacts of leprosy patients and an intervention arm in which this regimen will be reinforced with bedaquiline, 400 or 800 mg depending on weight, to be repeated once after four weeks for household contacts. The main study will be preceded by a phase 2 safety study.

Description:

Given the fact that the investigators are going to provide to healthy people a drug that has not been used before for this indication and which has only been conditionally approved for use in multi-drug resistant tuberculosis, they have first foreseen a phase 2 study in which BE-PEP will be provided to a limited number of contacts and in which safety will be closely monitored and evaluated by an independent data and safety monitoring board (DSMB). This will be done in a small village that is part arm 1 of the PEOPLE trial in which 8 new cases have been diagnosed since 2019 but no PEP has been provided. The investigators will conduct door-to-door screening in this village in June 2022 and offer a single dose of BE-PEP to a random sample of 150 people screened aged 5 years and above not meeting the exclusion criteria (active tuberculosis (TB) or leprosy or previously treated leprosy, known liver function or cardiac abnormalities, not able to swallow 100 mg bedaquiline tablets). Participants will be followed up closely with active monitoring for adverse events, including measurement of the corrected QT interval and liver function before and after administration, as well as gastro-intestinal (nausea, vomiting), nervous system-related (headache, dizziness) and cutaneous reactions. The remainder of the population of this village aged two years and above will be offered single dose rifampicin as per WHO recommendations. In a randomly sampled subset of 150 individuals receiving rifampicin only, the same stringent monitoring with ECG and liver function tests also applied in those receiving BE-PEP will be performed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 321
• Est. completion date: January 26, 2023
• Est. primary completion date: January 26, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 5 Years and older

Eligibility

Inclusion Criteria:

1. Being a permanent resident of the study village, in good state of health

2. Able and willing to provide informed consent

3. Age 5 years or above and weight of 20 kg or above

Exclusion Criteria:

1. Signs of active leprosy

2. Signs of active pulmonary tuberculosis (cough =2 weeks duration)

3. Signs of active extra-pulmonary tuberculosis (bluish-red nodules that cover the lymph nodes, bones or joints, or cervical glands with discharge)

4. History of liver- or kidney disease

5. Allergy to rifampicin or bedaquiline

6. Having received rifampicin or bedaquiline (if applicable) in the last 2-year period

7. Not able to swallow bedaquiline 100 mg tablets

8. Self-reported (suspected) pregnancy or breastfeeding

9. Concurrent (within the last three week period before D0) use of medications not included in the safe list (for bedaquiline only)

10. QT-prolongation of =450 msec in baseline ECG within the last week.

11. Jaundice or self-reported liver function abnormalities or hepatitis

12. Value of baseline ALT or AST >3x ULN within the last week. In case only ALT is available, this would suffice for enrollment

Related Conditions & MeSH terms

• Leprosy

Intervention

Drug:
• BE-PEP (Bedaquiline)
Single dose of Bedaquiline
• SDR-PEP
Single dose of Rifampicin
• BE-PEP (Rifampicine)
Single dose of Rifampicin

Locations

Country	Name	City	State
Comoros	Fondation Damien	Gege	Anjouan

Sponsors (2)

Lead Sponsor	Collaborator
Institute of Tropical Medicine, Belgium	Damien Foundation

Country where clinical trial is conducted

Comoros, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean difference in QTc interval between the two arms 24 hours after treatment administration	Mean difference in QTc interval between the two arms 24 hours after treatment administration	24 hours after treatment administration
Primary	Occurence of any predetermined study stopping criteria, which will trigger an immediate pause on enrollment	Occurence of any of the following predetermined study stopping criteria, which will trigger an immediate pause on enrollment: Death of a participant considered related to study drug; One or more participants experience an Serious Adverse Event (SAE) or Grade 4 Adverse Event (AE) or a persistent (upon repeat testing) Grade 4 laboratory abnormality that is determined to be related to study drug; Three or more participants experience a Grade 3 or greater AE of the same type (as per medical judgement) that is determined to be related to study drug; Three or more participants experience a persistent (upon repeat testing) Grade 3 laboratory abnormality related to the same laboratory parameter and considered to be related to study drug; Two or more participants experience QTc > 500 ms; One or more participants has Aspartate transaminase (AST) or Alanine transaminase (ALT) > 8x Upper limit of normal (ULN), in absence of causative explanation	Until day 30 after treatment administration
Secondary	Baseline frequency of ALT in the population	To determine the baseline frequency of ALT in the population.	At baseline
Secondary	Baseline frequency of AST elevations in the population	To determine baseline frequency of AST elevations in the population	At baseline
Secondary	Baseline frequency of QTc prolongations in the population	To determine baseline frequency of QTc prolongations in the population	At baseline
Secondary	Post administration QTc prolongation	Post administration QTc prolongation	24 hours after treatment administration
Secondary	Post-administration ALT level	Post administration ALT level	Day 14 after treatment administration
Secondary	Post-administration AST level	Post-administration AST level	Day 14 after treatment administration
Secondary	Frequency of potentially common adverse events such as gastro-intestinal (nausea, vomiting), nervous system-related (headache, dizziness) and cutaneous reactions	Frequency of potentially common adverse events such as gastro-intestinal (nausea, vomiting), nervous system-related (headache, dizziness) and cutaneous reactions	Until day 30 after treatment administration
Secondary	Occurrence of any (serious)AEs	Occurrence of any (serious)AEs	Until day 30 after treatment administration